Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study

Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study

Introduction: Reduction in bone mineral density (BMD) is a common side effect of androgen deprivation therapy (ADT). We aimed to examine the cross-sectional and longitudinal variation in BMD and associated bone markers in patients with nonmetastatic prostate cancer (PCa) managed with and without ADT...

Full description

Bibliographic Details
Main Authors:	Alice Wang, Nishi Karunasinghe, Lindsay Plank, Shuotun Zhu, Sue Osborne, Karen Bishop, Charis Brown, Tiffany Schwass, Jonathan Masters, Michael Holmes, Roger Huang, Christine Keven, Lynnette Ferguson, Ross Lawrenson
Format:	Article
Language:	English
Published:	SAGE Publishing 2017-10-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	https://doi.org/10.1177/1179554917733449

Similar Items

Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
by: Alice Wang, et al.
Published: (2021-07-01)

Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts.
by: Nishi Karunasinghe, et al.
Published: (2018-01-01)

Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand.
by: Nishi Karunasinghe, et al.
Published: (2019-01-01)

An examination of clinical differences between carriers and non-carriers of chromosome 8q24 risk alleles in a New Zealand Caucasian population with prostate cancer
by: Karen S. Bishop, et al.
Published: (2016-03-01)

A pilot study to investigate if New Zealand men with prostate cancer benefit from a Mediterranean-style diet
by: Sharon Erdrich, et al.
Published: (2015-07-01)

Nutrigenetics, nutrigenomics and selenium
by: Lynnette Robiin Ferguson, et al.
Published: (2011-04-01)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
by: Shtutman Michael, et al.
Published: (2010-04-01)

Nutrigenomics and Nutrigenetics Research in New Zealand, and Its Relevance and Application to Gastrointestinal Health
by: Lynnette Ferguson, et al.
Published: (2022-04-01)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
by: Iya Eze Bassey, et al.
Published: (2020-11-01)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
by: Shimajiri Shohei, et al.
Published: (2011-05-01)

Lacrimal sac adenocarcinoma managed with androgen deprivation
by: David H. Abramson, et al.
Published: (2020-09-01)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

Mortality outcomes and inequities experienced by rural Māori in Aotearoa New Zealand
by: Sue Crengle, et al.
Published: (2022-11-01)

Zinc in Prostate Health and Disease: A Mini Review
by: Nishi Karunasinghe
Published: (2022-12-01)

SNP-SNP interactions as risk factors for aggressive prostate cancer [version 1; referees: 2 approved]
by: Venkatesh Vaidyanathan, et al.
Published: (2017-05-01)

The early effects of rapid androgen deprivation on human prostate cancer
by: Shaw, G, et al.
Published: (2015)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
by: Justin H. Hwang, et al.
Published: (2019-11-01)

Androgen deprivation modulates the inflammatory response induced by irradiation
by: Lin Paul-Yang, et al.
Published: (2009-03-01)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
by: Giovanni Corona, et al.
Published: (2021-07-01)

Adult obesity management in New Zealand general practice: a review
by: Ross Lawrenson, et al.
Published: (2021-01-01)

Ethnic disparities in breast cancer survival in New Zealand: which factors contribute?
by: Sandar Tin Tin, et al.
Published: (2018-01-01)

Metabolic changes in patients with prostate cancer with androgen deprivation therapy
by: Maxim N. Peshkov, et al.
Published: (2020-06-01)

Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer
by: Laurence Klotz, et al.
Published: (2022-07-01)

Androgen deprivation therapy and hormonal status in men with COVID-19
by: A. A. Kamalov, et al.
Published: (2023-01-01)

Relationship between Androgen Deprivation Therapy and Abdominal Adipose Tissue
by: Federico Greco, et al.
Published: (2022-12-01)

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
by: Maree Pechlivanis, et al.
Published: (2021-12-01)

Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer
by: Caipeng Qin, et al.
Published: (2022-11-01)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
by: Jen‐Tsan Chi, et al.
Published: (2020-06-01)

Transcription factors involved in prostate gland adaptation to androgen deprivation.
by: Rafaela Rosa-Ribeiro, et al.
Published: (2014-01-01)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
by: Rahul Jena
Published: (2020-01-01)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
by: Jui-Ming Liu, et al.
Published: (2020-01-01)

Antifracture agents for prostate cancer patients on androgen deprivation therapy
by: Bhupendra P Singh, et al.
Published: (2010-01-01)

Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?
by: Piotr Zareba, et al.
Published: (2016-04-01)

Androgen deprivation therapy (castration therapy) and pedophilia: What’s new
by: Mauro Silvani, et al.
Published: (2015-09-01)

Re: Final Report of the Intergroup Randomized Study of Combined AndrogenDeprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
by: Malcolm D. Mason, et al.
Published: (2015-06-01)

Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood
by: Allison B. Reiss, et al.
Published: (2023-12-01)

Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
by: Yutaka Yamamoto, et al.
Published: (2024-03-01)

Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
by: Shangwei Zhong, et al.
Published: (2022-02-01)

Influence of androgen deprivation therapy on glucose metabolism and ambulatory glucose profile
by: E. Yu. Grickevich, et al.
Published: (2021-05-01)

Chlormadinone acetate is effective for hot flush during androgen deprivation therapy
by: Hidekazu Koike, et al.
Published: (2013-09-01)